Effect of paclitaxel in gefitinib-resistant non-small cell lung cancer (NSCLC) treatment during the COVID-19 pandemic.

被引：0
|
作者：
Mohiuddin, Md [1 ]
Kasahara, Kazuo [1 ]
机构：
[1] Kanazawa Univ, Dept Resp Med, Kanazawa, Ishikawa, Japan
来源：
CLINICAL CANCER RESEARCH | 2020年 / 27卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P27
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Overexpression and extended degradation rate of Axl in acquired gefitinib-resistant non-small cell lung cancer cells
    Kim, Donghwa
    Bach, Duc-Hiep
    Hong, Ji-Young
    Park, Hyen Joo
    Lee, Sang Kook
    CANCER RESEARCH, 2018, 78 (13)
  • [22] Role of Neoadjuvant Chemotherapy in Non-small Cell Lung Cancer in the COVID-19 Pandemic
    Karaman, Elanur
    Ulas, Arife
    Onder, Arif Hakan
    Deligonul, Adem
    Orhan, Sibel O.
    Pekcolaklar, Atilla
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2022, 14 (09)
  • [23] Apoptotic effect of a single compound derived from natural product in Gefitinib-resistant non-small cell lung cancer cells
    Fan, Xing-Xing
    Wong, Maria Pik
    Cao, Zhi-Wei
    Li, Na
    Wu, Jin-Lin
    Zhou, Hua
    Jiang, Zhi-Hong
    Liu, Liang
    Leung, Elaine Lai-Han
    CANCER RESEARCH, 2014, 74 (19)
  • [24] Carboplatin and Weekly Paclitaxel for the Treatment of Advanced Non-small Cell Lung Cancer (NSCLC) During Pregnancy
    Azim, Hatem A., Jr.
    Scarfone, Giovanna
    Peccatori, Fedro A.
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (04) : 559 - 560
  • [25] SYNERGISTIC INTERACTIONS OF GEFITINIB, AFATINIB, CETUXIMAB AND DASATINIB AGAINST GEFITINIB RESISTANT NON-SMALL CELL LUNG CANCER (NSCLC)
    Chang, Alex Y.
    Wang, Miao
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (11) : S453 - S453
  • [26] A phase II trial of weekly paclitaxel (P) and gefitinib (G) in patients (pts) with gefitinib-refractory or -resistant non-small cell lung cancer (NSCLC).
    Kasahara, K
    Sone, T
    Kimura, H
    Yoshimoto, A
    Araya, T
    Iwasa, KI
    Shirasaki, H
    Shintani, H
    Fujimura, M
    Nakao, S
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 639S - 639S
  • [27] Discovery of hybrid Hsp90 inhibitors and their anti-neoplastic effects against gefitinib-resistant non-small cell lung cancer (NSCLC)
    Jeong, Chul-Ho
    Park, Hee Baek
    Jang, Won Jun
    Jung, Su Hyun
    Seo, Young Ho
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2014, 24 (01) : 224 - 227
  • [28] Role of adenosine A2a receptors in the growth control of a gefitinib-resistant non-small cell lung cancer cell growth
    Noguchi, Maki
    Kuzumaki, Naoko
    Nagasawa, Atsumi
    Narita, Michiko
    Narita, Minoru
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2013, 121 : 197P - 197P
  • [29] Effect of gefitinib challenge to initial treatment with non-small cell lung cancer
    Chen, Xiaofeng
    Li, Wei
    Hu, Xiaoli
    Geng, Yiting
    Wang, Rong
    Yin, Yongmei
    Shu, Yongqian
    BIOMEDICINE & PHARMACOTHERAPY, 2011, 65 (08) : 542 - 546
  • [30] Treatment of non-small cell lung cancer (NSCLC)
    Zarogoulidis, Konstantinos
    Zarogoulidis, Paul
    Darwiche, Kaid
    Boutsikou, Efimia
    Machairiotis, Nikolaos
    Tsakiridis, Kosmas
    Katsikogiannis, Nikolaos
    Kougioumtzi, Ioanna
    Karapantzos, Ilias
    Huang, Haidong
    Spyratos, Dionysios
    JOURNAL OF THORACIC DISEASE, 2013, 5 : S389 - S396
12345